Market Cap 778.45M
Revenue (ttm) 297.20M
Net Income (ttm) -11.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3.98%
Debt to Equity Ratio 0.02
Volume 4,000
Avg Vol 5,820
Day's Range N/A - N/A
Shares Out 671.07M
Stochastic %K 87%
Beta 0.65
Analysts Sell
Price Target $37.00

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 71 524 7400
Fax: 31 71 524 7445
Address:
Darwinweg 24, Leiden, Netherlands
Latest News on PHGUF
No data available.